<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118336</url>
  </required_header>
  <id_info>
    <org_study_id>2016-39</org_study_id>
    <secondary_id>2016-003196-21</secondary_id>
    <nct_id>NCT03118336</nct_id>
  </id_info>
  <brief_title>Impact of Empaglifozine on Cardiac Ectopic Fat</brief_title>
  <acronym>EMPACEF</acronym>
  <official_title>Impact of Empaglifozine on Cardiac Ectopic Fat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is substantial evidence supporting the fact that ectopic fat accumulation is an
      important contributor to type 2 diabetes complications and cardiovascular risk [1].
      Epicardial adipose tissue (EAT), located between the myocardium and the visceral layer of the
      pericardium has been associated with atrial fibrillation and with coronary artery disease [2,
      3] and its abundance predicts the number of cardiac events within 8 years [4]. In addition,
      myocardial steatosis has been shown to be an independent predictor of diastolic dysfunction
      [5] [6]. Furthermore, in type 2 diabetic patients, bariatric surgery can reduce cardiac
      ectopic fat accumulation and improve cardiac function [7] [8]. When added to standard care,
      10 or 25 mg/d of empagliflozin, an inhibitor of sodium-glucose cotransporter 2 (iSGLT2),
      significantly reduces the risk of death, cardiovascular death, and hospitalisation for heart
      failure among individuals with type 2 diabetes and established cardiovascular disease when
      compared to placebo [9]. The mechanisms of empagliflozin-improved cardiovascular outcomes in
      type 2 diabetic patients at high risk of cardiovascular events are not known. We hypotheses
      that empaglifozin could modulate cardiac ectopic fat and cardiac metabolism in obese type 2
      diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2017</start_date>
  <completion_date type="Actual">February 7, 2020</completion_date>
  <primary_completion_date type="Actual">February 7, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiac morphology</measure>
    <time_frame>12 weeks</time_frame>
    <description>magnetic resonance imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>epicardial adipose tissue volume</measure>
    <time_frame>12weeks</time_frame>
    <description>magnetic resonance imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>myocardial triglyceride</measure>
    <time_frame>12weeks</time_frame>
    <description>proton magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatic triglyceride content</measure>
    <time_frame>12 weeks</time_frame>
    <description>proton magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial PCr/ATP ratio</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>empaglifozine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10Mg Tab</intervention_name>
    <description>1 tablet of 10 milligrams per bone 1 time a day during 12 weeks</description>
    <arm_group_label>empaglifozine group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years,

          -  Type 2 diabetes based on the disease diagnostic criteria as described by the WHO,

          -  HbA1c &gt; 7% and &lt; 10 %

          -  Stable glucose-lowering therapy for at least 3 weeks before randomization

          -  Estimated glomerular filtration rate &gt; 60/ml (MDRD)

          -  Signed informed consent form obtained prior to any study procedure

        Exclusion Criteria:

          -  Evolutive or planned pregnancy during the six months

          -  Lactation

          -  Recent weight loss (&gt;5% of body weight within one month),

          -  Treatment modifying adipose distribution such as corticoids

          -  Acute coronary syndrome or instable angina during the last 2 months,

          -  MRI contraindication (metal cardiac valve, pace maker, metal foreign body,
             claustrophobia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>anne dutour</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiac Complexes, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

